Ординатура / Офтальмология / Английские материалы / Electrophysiology of Vision_Lam_2005

508

Autosomal dominant vitreoretinochoroidopathy, 347

Autosomal recessive achromatopsia, 262

Autosomal recessive disorder, 218

Bardet–Biedl syndrome, 206 Alstrom syndrome, 208 Mckusick–Kaufman syndrome,

207 PAHX gene, 208

PEX1 and PEX2 genes, 208 Refsum disease, 208 Zellweger syndrome, 208

Basal RPE membrane, 118 Behc¸et disease, 353 Berson color test, 265 Best disease, 291

Binocular beat technique, 166 Binocular beat VEP, 143

beat frequency, 144 Binocular testing, 161

Birdshot retinochoroidopathy, 357 Blue cone monochromatism, 264 Blue flash stimulus, 26

Branch retinal artery occlusion (BRAO), 383

Branch retinal vein occlusion (BRVO), 391

Brunescent cataract, 453

Cancer-associated retinopathy, 187, 367

Carbonic anhydrase inhibitors, 118

Central areolar choroidal dystrophy, 337

Central retinal artery occlusion (CRAO), 380

Central retinal dysfunction, 303 Central retinal vein occlusion

(CRVO), 383 Neovascularization, 386

Index

[Central retinal vein occlusion (CRVO)]

ERG retinal sensitivity, 389 Central scotoma, 356

Central vision, 332 Cerebral cortex, 143 cGMP cascade, 298

Checkerboard stimulus, black and white, 100

Checkerboard stimulus, 101 Chiasmal compression, 484 Choroidal melanoma, 355 Circumpapillary telangiectatic

microangiopathy, 486 Cisplatin, 434

induced neurotoxicity, 434 neurotoxicity, 434

Clinical classification, 189 Compressive optic neuropathy,

484 Conception, 152 Conditioning flash, 45

Cone dystrophy, 257, 293 Cone pedicles, 55

Cone photoreceptor activation model, 298

Cone photoreceptor cGMP-gated channel, 262

Cone–rod dystrophy, 219

rod amplitude progression, 222 Congenital stationary night

blindness, 244, 460 Consanguineous marriages, 252 Cornea, 112

Coronary arterial disease, 397 Cortical blindness, 474 Cortical visual impaired, 487 Corticosteroid, 450 Corticosteroid therapy, 485

Dark adaptation, 114, 159 Dark adaptation phase, 116 Dark adaptometry, 257 Dark-adapted responses, 188

Index

Deferoxamine, 425 therapy, 425 toxicity, 426

Delayed visual maturation, 156 infancy, 156

Dense vitreous hemorrhage, 453 Depolarization, 6

Deutan, 261

Deutanomalous trichromats, 262 Deutanopes, 262

Diabetic macular edema, 394 Diabetic retinopathy, 393 Dichromats, 261

Diffuse retinal pigmentary alteration, 191

Diffuse unilateral subacute neuroretinitis, 360

Disease classification, 188 genetic categorization, 188 genetic mutations, 189 mechanism, 188 molecular diagnosis, 188

Duchenne and Becker muscular dystrophies, 450

Eccentric fixation, 19

EEG alpha contribution, 143 Encephalopathy, 459

Enhanced S-cone syndrome, 215 EOG test session, 114

ERG and EOG impairment, 418 ERG recording, 19, 67

ERG responses, 345 ERP abnormality, 40 Ethambutol, 433

optic neuropathy, 433 Extrastriate cortex, 141

Familial exudative vitreoretinopathy, 346

Farnsworth D15 panel hue discrimination test, 265

Fast oscillation, 109 First-order kernel, 67

509

Fixation, 161

Flash VEP amplitude, 452 Flash VEP, 137

Flex retina of Kandori, 261 Fluorescein angiography, 280, 353 Focal lesions, 353

histoplasmosis, 353 toxoplasmosis, 353

Foveal pit, 152

Foveal retinoschisis, 306 Foveal testing, 67 Friedreich ataxia, 474, 489 Full-field ERG, 243, 344

Full-field ERG responses, 249 OFF-response, 249 ON-response, 249

Fundus albipunctatus, 188, 256 Rod ERG responses, 188

Fundus flavimaculatus, 284

Genetic mutations, 344 Gentamicin, 432 Geographic choroiditis, 356 Giant cell arteritis, 381 Glaucoma, 474

Globus pallidus internus, 491 Goldmann–Favre syndrome, 218,

343

ERG signal, 219

Hardy–Rand–Rittler tests, 261 Helicoid peripapillary

chorioretinal degeneration, 337

Helicoid peripapillary choroidopathy, 356

Hemoglobin SC disease, 396 Hereditary hemoglobulinopathies,

396

Hereditary optic neuropathies, 474

Hereditary progressive arthroopthalmopathy, 344

510

Heterozygous missense mutation, 254

Histopathology, 347

Human immunodeficiency virus, 449

Hyperopia, 452 Hyperosmolarity-induced

response, 118 Hyperpolarization, 6 Hypertension, 397

Cushing’s disease, 397 Hypoperfusion, 380

Idiopathic intracranial hypertension, 483

Idiopathic polypoidal choroidal vasculopathy, 399

Indomethacin, 435 indomethacin-induced corneal

deposits, 435

Inner retinal dysfunction, 383 Intraocular tamponade, 456 Intravenous thrombolytic

medications, 381

Iris pigment epithelium, 457 Iron overload, 425 Ischemia, 482

Ischemic optic neuropathy, 474 Isoluminance, 141

Kynurenic acid, 251

Laminar cribosa, 380

Lateral canthus electrode, 112 Leber congenital amaurosis, 50,

203, 245

Leber hereditary optic neuropathy, 486 Leukodystrophies, 474 Light adaptation, 114

Light-peak to dark-trough amplitude ratio, 171

Liver dysfunction, 450

Index

Local retinal function, 185 Low density lipoprotein

(LDL), 209

Macular disorders, 277 Macular dysfunction, 92, 277 Macular dystrophy, 257 Macular inflammation, 353 Macular pigmentary alteration,

302

Medical canthus electrode, 112 Medical management, 185 Melanoma-associated retinopathy,

369

Methanol poisoning, 414 Mitochondrial retinopathy, 213 Mizuo–Nakamura phenomenon,

260, 294 Monochromats, 262 Monocular testing, 161 Monocular visual pathway

dysfunction, 132 Mucopolysaccharide matrix, 108 Mu¨ ller cells, 414

Multifocal choroiditis with panuveitis, 366

Multifocal ERG, 185, 277 Multifocal ERG impairment, 281 Multifocal VEP, 141

Myopia, 452

Myopic retinal degeneration, 346, 453

Myotonic dystrophy, 450

Neuronal ceroid lipofuscinosis, 210 Batten disease, 211

Kufs disease, 211

Progressive pigmentary retinal degeneration, 211

Night vision impairment, 244 Non-organic or functional visual

loss, 450 hysteria type, 450 malingering type, 450

Index

Non-photic EOG responses, 118 Normal ornithine

aminotransferase activity, 336

Normal trichromat, 261 North Carolina macular

dystrophy, 308 Nougaret CSNB, 253 Nutritional optic neuropathy,

410, 473 Nyctalopia, 461 Nyctalopin, 246 Nystagmus, 114

Ocular antigens, 355 Ocular dysfunction, 123 Ocular hypertension, 474 Ocular siderosis, 411

ocular toxicity, 411

Ocular vascular disorders, 377 Behc¸et disease, 377

Bruch’s membrane, 379 choriocapillaris, 379 retinal vasculitis

disorders, 377 vascular occlusion, 377

Oguchi disease, 259, 294 Olivopontocerebellar

atrophy, 474

‘‘On’’ and ‘‘off’’ pathways, 54 Open-angle glaucoma, 457 Ophthalmic artery hypoperfusion,

380

Optical coherence tomography, 296, 353, 485

Optic chiasm, 256

Optic nerve head component, 84 Optic nerve head drusen, 474 Optic nerve head vessel, 345 Optic nerve pallor, 484

Optic neurities=multiple, sclerosis, 474

Optic neuropathies, 474 Optimal check size, 100 stimulus size, 100

511

Organ of Corti of degeneration, 205

Oscillatory potential, 459

Pallidotomy, 490

Papilledema, 474 Paraneoplastic syndromes, 367 Parkinson disease, 474

Pars planitis/intermediate uveitis, 352

Patient tolerance, 9 Pattern dystrophy, 302

Pattern ERG amplitude, 476 Pattern reversal VEP, 133 Pattern stimulus, 129 Pattern onset=offset VEP, 135 Peripheral rod function, 294 Photopic hill, 34

Photopic negative response (PhNR), 381

Photopic negative response, 477 Photopic retinal function, 68 Photoreceptor activity, 21 Photoreceptor dysfunction, 108 Photoreceptor-specific homeo box

gene, 203 Phototransduction

efficiency, 37 process, 52

Phototransduction cascade, 253 Physiologic classification, 189 Pigment dispersion

syndrome, 457 Pigmental retinopathy, 191

Pigmentary retinal degeneration, 192

Poor fixation, 72 erroneous clinical

interpretation, 72 Posterior ischemic optic

neuropathy, 482 Posterior uveitis, 352 Post-rubella retinopathy, 214 Post-rubella syndrome, 214

512

Post-syphilitic syndrome, 214 Preadaptation, 114

Presumed ocular histoplasmosis syndrome, 365

Preterm infants, 156

Primary cone dysfunction, 294 Primary open angle glaucoma, 474 Primary visual cortex, 127

Probe flash, 46 Probe stimulus, 45

Progressive cerebellar dysfunction, 488

Protan, 261

Protanomalous trichromats, 262 Protanopes, 262

Proximal retinal dysfunction, 251 Pseudomotor cerebri, 483 Pseudo-POHS, 366 Psychophysical threshold, 43

Quinine toxicity, 421

Recoverin-associated retinopathy, 369

Refractile nodules, 485 Response density, 78 Retina, 112

Retinal atrophy, 192 Retinal detachment, 449 Retinal dysfunction, 211

Retinal dystrophies, 50, 188, 191 Retinal ganglion cell dysfunction,

422, 486 Retinal illuminance, 7

Retinal ischemia, 25, 380 Retinal pigment epithelium, 48,

105

Retinal pigment proliferation, 298 Retinal pigmentary degeneration,

199

Retinal recovery, 13, 45 Retinal resting potential, 456 Retinal sensitivity, 30, 32 Retinitis pigmentosa, 50, 192

Batten disease, 192

Index

[Retinitis pigmentosa] ERG responses, 194 ERG testing, 194

full-field ERG responses, 194 X-linked recessive RP, 194

Retinitis punctata albescens, 257 Retinol (vitamin A) metabolism,

194

Retinopathy of prematurity (ROP), 392

Retrobulbar optic neuritis, 478 Rhodopsin kinase gene, 259 Rhodopsin mutations, 254 Riggs type, 252

Rod activation, 43 Rod–cone response, 202, 245 Rod monochromatism, 262 Rod photoreceptors, 332 Rod sensitivity, 153

Saccadic waveform, 114 Salmon patch choroidopathy,

358

Scalar template, 79 Scalp muscle tension, 143

Scheie’s classification, 397 Scotopic retinal function, 69 Second-order kernel, 81 Sector RP, 199

Sedative agents, 157 Semi-decussation, 127 Senile macular degeneration,

278 Sensitivity, 153

Serpiginous choroiditis, 356 Short wavelength automated perimetry, 476

Sickle cell disease, 396 Signal-to-noise ratio, 197

a-wave, 201 b-wave, 201

Goldmann and Tu¨ binger perimeters, 197

Sildenafil, 431

Silicone oil injection, 457

Index

Sjo¨gren’s syndrome, 416 ERG and EOG impairment,

418 hydroxychloroquine

maculopathy, 416 Slow oscillation, 109 Spinocerebellar degeneration,

474

Square-shaped waveform, 113 Standing potential, 105 Stargardt disease, 286

Stargardt macular dystrophy, 221, 284

Choroidal silence, 285 Dark choroid, 285

Stationary cone dysfunction disorders, 243, 261

Stationary night blindness disorders, 243 Steady-state pattern ERG responses, 96

Stickler syndrome, 344 Stimulator-ophthalmoscope

devices, 68 Stimulus intensity, 169 Stimulus luminance, 7 Strabismus, 114 Striate cortex, 129 Strip width, 159

Subclinical demyelination, 482 Surgical optic canal

decompression, 485 Sweep VEP, 139

Sweep contrast frequency VEP, 141

Sweep spatial frequency stimulus, 139

Sympathetic ophthalmia, 354 Sympathizing eye, 355 Synaptic activity, 6

Thioridazine retinopathy, 419 Thyroid associated

ophthalmopathy, 458 Thyroid dysfunction, 450

513

Tracheal intubation, 159 Transepithelial potential, 109 Transient pattern ERG

responses, 96 Transient VEP responses, 133 Traumatic optic neuropathy,

474 Tritan, 261

Type 5 collapsin responsemediator protein, 370

Unilateral or asymmetric abnormality, 20

Unilateral RP, 199 Usher syndrome, 204 Uveitis, 352

Ventriculo-peritoneal shunt, 483

VEP response, 202, 347, 451 Very low density lipoprotein

(VDRL), 209 Vigabatrin, 428

GABA, 428 therapy, 429

visual field constrictions, 431 Visual acuity, 161, 262, 332

best-fit curve, 161 central vision, 332

Visual afferent input, 453 Visual cortical activity, 123 Visual electrophysiologic testing,

185

Visual field map, 141 Visual function, 346 Visual prognosis, 355, 479 Vitamin A, 408

11-cis retinol, 408 Crohn’s disease, 408 night blindness, 409 rod–cone dystrophy, 409 xerophthalmia, 408

Vitiligenous chorioretinitis, 343

514

Vitrectomy, 457 Vitreous syneresis, 344

Vitroretinal disorders, 343 Vogt–Koyanagi–Harada disease,

354 Voltage-gated sodium

channels, 84

Index

Wagner vitreoretinopathy, 345

X-linked pedigree, 306 X-linked recessive, 261 X-linked retinoschisis, 303, 335 X-linked RP carriers, 201